Expression and Significance of TSGF, CEA and AFP in Patients Before and after Radical Surgery for Colon Cancer |
Hu, Yi
(Department of Oncology, Chinese PLA General Hospital)
Wang, Jing-Liang (Department of Oncology, Chinese PLA General Hospital) Tao, Hai-Tao (Department of Oncology, Chinese PLA General Hospital) Wu, Bai-Shou (Department of Oncology, Chinese PLA General Hospital) Sun, Jin (Department of Oncology, Chinese PLA General Hospital) Cheng, Yao (Department of Oncology, Chinese PLA General Hospital) Dong, Wei-Wei (Department of Oncology, Chinese PLA General Hospital) Li, Rui-Xin (Department of Oncology, Chinese PLA General Hospital) |
1 | Benhaim L, Loupakis F, Labonte MJ, et al (2012). Selecting the best targeted agent in first-line treatment of unresectable liver metastases from colorectal cancer: does the bench have the answers? J Hepatobiliary Pancreat Sci, 19, 528-35. DOI ScienceOn |
2 | Church D, Midgley R, Kerr D (2012). Biomarkers in early-stage colorectal cancer: ready for prime time? Dig Dis, 30, 27-33. DOI ScienceOn |
3 | Clark MJ, Robien K, Slavin JL (2012). Effect of prebiotics on biomarkers of colorectal cancer in humans: a systematic review. Nutr Rev, 70, 436-43. DOI ScienceOn |
4 | de Cuba EM, Kwakman R, van Egmond M, et al (2012). Understanding molecular mechanisms in peritoneal dissemination of colorectal cancer: future possibilities for personalised treatment by use of biomarkers. Virchows Arch, 461, 231-43. DOI ScienceOn |
5 | Duffy MJ, van Dalen A, Haglund C, et al (2007). Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer, 43, 1348-60. DOI ScienceOn |
6 | Duffy MJ (2013). Tumor markers in clinical practice: a review focusing on common solid cancers. Med Princ Pract, 22, 4-11. DOI ScienceOn |
7 | Efferth T (2012). Signal transduction pathways of the epidermal growth factor receptor in colorectal cancer and their inhibition by small molecules. Curr Med Chem, 19, 5735-44. DOI |
8 | Fiorentino F, Hunt I, Teoh K, et al (2010). Pulmonary metastasectomy in colorectal cancer: a systematic review and quantitative synthesis. J R Soc Med, 103, 60-6. DOI ScienceOn |
9 | Herrere MA, Chu TM, Pinsky CM, et al (1979). Preoperative carcionembryonic antigen level as prognostic indicator in colorectal cancer. N Engl J Med, 299, 448-51. |
10 | Koukourakis GV, Sotiropoulou-Lontou A (2011). Targeted therapy with bevacizumab (Avastin) for metastatic colorectal cancer. Clin Transl Oncol, 13, 710-4. DOI ScienceOn |
11 | Lawicki S, Mroczko B, Szmitkowski M (2002). Neoplasm markers useful for diagnosis and monitoring of colonic neoplasms. Postepy Hig Med Dosw, 56, 617-34. |
12 | Akagi Y, Adachi Y, Kinugasa T, et al (2013). Lymph node evaluation and survival in colorectal cancer: review of population-based, prospective studies. Anticancer Res, 33, 2839-47. |
13 | Amayo AA, Kuria JG (2009). Clinical application of tumour markers: a review. East Afr Med J, 86, S76-83. |
14 | Lupinacci R, Penna C, Nordlinger B (2007). Hepatectomy for resectable colorectal cancer metastases-indicators of prognosis, definition of resectability, techniques and outcomes. Surg Oncol Clin N Am, 16, 493-506. DOI ScienceOn |
15 | Molinari C, Casadio V, Foca F, et al (2013). Gene methylation in rectal cancer: Predictive marker of response to chemoradiotherapy? J Cell Physiol, [Epub ahead of print]. |
16 | Pritchard CC, Grady WM (2011). Colorectal cancer molecular biology moves into clinical practice. Gut, 60, 116-29. DOI ScienceOn |
17 | Sasahira T, Ueda N, Kurihara M, et al (2013). Tropomyosin receptor kinases B and C are tumor progressive and metastatic marker in colorectal carcinoma. Hum Pathol, 44, 1098-106. DOI ScienceOn |
18 | Spelt L, Andersson B, Nilsson J, et al (2012). Prognostic models for outcome following liver resection for colorectal cancer metastases: A systematic review. Eur J Surg Oncol, 38, 16-24. DOI ScienceOn |
19 | Soreide K, Nedrebø BS, Knapp JC, et al (2009). Evolving molecular classification by genomic and proteomic biomarkers in colorectal cancer: potential implications for the surgical oncologist. Surg Oncol, 18, 31-50. DOI ScienceOn |
20 | Stillwell AP, Ho YH, Veitch C (2011). Systematic review of prognostic factors related to overall survival in patients with stage IV colorectal cancer and unresectable metastases. World J Surg, 35, 684-92. DOI |
21 | Yamashita K, Watanabe M (2009). Clinical significance of tumor markers and an emerging perspective on colorectal cancer. Cancer Sci, 100, 195-9. DOI ScienceOn |
22 | Turriziani M, Fantini M, Benvenuto M, et al (2012). Carcinoembryonic antigen (CEA)-based cancer vaccines: recent patents and antitumor effects from experimental models to clinical trials. Recent Pat Anticancer Drug Discov, 7, 265-96. DOI |
23 | Wu XY, Huang XE, You SX, et al (2013). Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer. Asian Pac J Cancer Prev, 14, 2019-22. 과학기술학회마을 DOI ScienceOn |
24 | Xu HX, Huang XE, Qian ZY, et al (2011). Clinical observation of Endostar(R) combined with chemotherapy in advanced colorectal cancer patients. Asian Pac J Cancer Prev, 12, 3087-90. |
25 | Yu B, Xu PZ, Wang QW, et al (2009). Clinical value of tumour specific growth factor (TSGF) and carbohydrate antigen-125 (CA-125) in carcinoma of the endometrium. J Int Med Res, 37, 878-83. DOI |
26 | Yu DS, Huang XE, Zhou JN, et al (2012). A Comparative Study on the Value of Anal Preserving Surgery for Aged People with Low Rectal Carcinoma in Jiangsu, China. Asian Pacific J Cancer Prev, 13, 2339-40. 과학기술학회마을 DOI ScienceOn |
27 | Zhang LQ, Huang XE, Wang J, (2011). The cyclin D1 G870A polymorphism and colorectal cancer susceptibility: a metaanalysis of 20 populations. Asian Pac J Cancer Prev, 12, 81-5. |
28 |
Zhou G, Niu L, Chiu D, et al (2012). Changes in the expression of serum markers CA242, CA199, CA125, CEA, TNF- |
29 | Zorcolo L (2006). Biomolecular prognostic factors in colorectal cancer. Chir Ital, 58, 733-42. |
![]() |